The LEADER investigators report that treatment with the glucagon-like peptide-1 receptor agonist liraglutide may be of particular benefit in the oldest patients with type 2 diabetes.
Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future [read more].
The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.
Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.
Results of the Harmony Outcomes trial indicate that adding the glucagon-like peptide-1 receptor agonist albiglutide to standard care may reduce cardiovascular risk among patients with type 2 diabetes and existing cardiovascular disease.
The authors assess the risk of hospitalization due to HF with the use of dipeptidyl peptidase-4 inhibitors compared to glucagon like peptide-1 receptor agonists [read more]. Dawwas GK, Smith SM, Park H. Cardiovasc Diabetol 2018; 17: 102. doi: 10.1186/s12933-018-0746-4
Research shows that starting second-line sulfonylurea treatment is associated with an increased risk for cardiovascular and hypoglycemic events among patients with type 2 diabetes in clinical practice, although the risk is less if they continue using metformin rather than switching completely.
This review presents the evidence from old and recent trials relevant to optimal blood pressure levels in diabetes mellitus, aiming to shed light in this major clinical question [read more]. Papadopoulou E et al. J Hum Hypertens 2018. doi: 10.1038/s41371-018-0079-5
The authors examined the relationship between sleep disturbance and self-care in adults with type 2 diabetes, including both subjective and objective sleep assessments and controlling for potential covariates [read more]. Zhu B et al. Acta Diabetol 2018. doi: 10.1007/s00592-018-1181-4
A real-world study based on DECLARE-TIMI 58 inclusion and outcome criteria shows that dapagliflozin not only reduces cardiovascular risk among patients with type 2 diabetes, in line with the original trial results, but may also lower all-cause mortality risk.
Registry data from Denmark and Sweden uphold the cardioprotective effects of liraglutide observed in randomized trials, with the strongest effects seen in patients with established cardiovascular disease.
The addition of empagliflozin reduces nighttime blood pressure in older diabetes patients who have nocturnal hypertension despite medication including angiotensin receptor blockers, show findings from a randomized trial.
An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.
A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.
Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.
Themed collections
Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.
Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.
